Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Clinical trial NCT04659434 · UNKNOWN

Trial details

NCT number: NCT04659434
Sponsor: Qian Wenbin
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B Cell Lymphoma Relapsed Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma

Start date: 2020-12-10
Primary completion: 2022-12-10
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.